AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02816736
Drug: LCZ696
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects previously taking no or low-dose ACEI or ARB, or who have an eGFR \< 30 mL/min/1.73m²: starting dose of LCZ696 = 50 mg po BID.~Subjects taking an ARB at greater than low dose: starting dose of LCZ696 = 100 mg po BID.~Subjects taking an ACEI at greater than low dose: starting dose of LCZ696 = 100 mg po BID.~\* At Investigator discretion, study drug may be started at the low dose if there are any concerns regarding tolerability.~Dose adjustments will be performed every 2 weeks by doubling the dose of LCZ696 up to the target max dose of 200 mg po BID as tolerated.~The doses of LCZ696 are 50mg (one low-dose (50mg) tablet), 100mg (one high-dose (100mg) tablet), and 200mg (two high-dose (100mg) tablets.) These doses are equivalent to 24/26 mg, 49/51 mg, and 97/103 mg commercial Entresto™, respectively.
Trial: NCT02816736
Drug: LCZ696 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCZ696 placebo tablets will be supplied to match the low-dose (50mg) and high-dose (100mg) active LCZ696 tablets. Dosing for LCZ696 placebo will mirror dosing for active valsartan (the same number of low or high-dose tablets will be given.)
Trial: NCT01515423
Drug: PP3M 175 mg eq.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type= exact number, unit= mg eq., number= 175, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
Trial: NCT01515423
Drug: PP3M 263 mg eq.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type= exact number, unit= mg eq., number= 263, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
Trial: NCT01515423
Drug: PP3M 350 mg eq.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type= exact number, unit= mg eq., number= 350, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
Trial: NCT01515423
Drug: PP3M 525 mg eq.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type= exact number, unit= mg eq., number= 525, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
Trial: NCT01515423
Drug: PP1M 50 mg eq.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type= exact number, unit= mg eq., number= 50, form= injection, route= intramuscular use. One injection every month for 48 weeks.
Trial: NCT01515423
Drug: PP1M 75 mg eq.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type= exact number, unit= mg eq., number= 75, form= injection, route= intramuscular use. One injection every month for 48 weeks.
Trial: NCT01515423
Drug: PP1M 100 mg eq.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type= exact number, unit= mg eq., number= 100, form= injection, route= intramuscular use. One injection every month for 48 weeks.
Trial: NCT01515423
Drug: PP1M 150 mg eq.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type= exact number, unit= mg eq., number= 150, form= injection, route= intramuscular use. One injection every month for 48 weeks.
Trial: NCT01722708
Drug: Clindamycin
RxNorm normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral clindamycin 300 Milligrams\*2/Day for a week
Trial: NCT01110018
Drug: GSK573719 (INHALATION POWDER)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500μg inhalation powder delivered via Novel Dry Powder Inhaler. GSK573719 1000μg per dose (2x 500μg strips in device).
Trial: NCT01459133
Drug: Technosphere® Insulin Inhalation System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Site, Single Subject use of Technosphere® Insulin Inhalation System
Trial: NCT02452606
Drug: Stalevo®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Sleep disorders in Parkinson's disease~* Analysis by Parkinson's Disease Sleep Scale(PDSS) scores.~* If the PDSS score is improving at least 15 percent than the baseline score, It can be determined to be effective.
Trial: NCT02056223
Drug: Intravenous paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/Kg every 6 hours for three days
Trial: NCT02056223
Drug: Intravenous ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 -5-5 mg/Kg once a day for three days
Trial: NCT04535141
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It will be a de-identified pill created by investigational drug services at University of North Carolina
Trial: NCT01268670
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects will receive topical LET and oral ibuprofen.
Trial: NCT02401269
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01075789
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viscous, coloured, sucrose flavoured gel solution to match xylocaine viscous in appearance, normal saline administered intranasally to the nasal turbinates and nasopharynx.
Trial: NCT01932333
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 1: Participants will receive placebo once a day on Day 1 for Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 for Period 2; Cohort 2: Participants will receive placebo once a day on Day 1 for Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 for Period 2.
Trial: NCT01669291
Drug: Bravelle and Menopur
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bravelle and Menopur are used for controlled ovarian stimulation (COH)
Trial: NCT01669291
Drug: Agonist
RxNorm normalized name: Dopamine agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agonist (Lupron) is used to suppress endogenous pituitary LH for the premature LH surges.
Trial: NCT01669291
Drug: Antagonist
RxNorm normalized name: Purine antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganirelix acetate or cetrorelix acetate Agonist is used to suppress endogenous pituitary LH for the premature LH surges.
Trial: NCT00007631
Drug: Tretinoin 0.1% cream or placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00659191
Drug: GSK1265744
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00842673
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo to match ST101 tablets
Trial: NCT00122382
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo IV, monthly, methotrexate weekly for 12 months followed by abatacept 10 mg/kg IV monthly, methotrexate weekly for 12 months
Trial: NCT00748592
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in this arm will be administered 3 capsules of placebo 30 minutes before bedtime for two consecutive nights in the sleep lab.
Trial: NCT01615367
Drug: Typically consists of at least one FDA-approved mood stabilizer
RxNorm normalized name: omega-3 acid ethyl esters (USP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy will be conducted by experts in BD treatment and will follow the empirically-supported treatment algorithm for BD that has been developed and recently revised. The foundation of TAU is to maintain treatment with at least one Food and Drug Administration approved mood stabilizer. For TAU, medication and dosage changes are allowed as needed as long as the change is recommended based on the guidelines and participants remain on a mood stabilizer.
Trial: NCT04935541
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After Remifentanil infusion was given for 10 minutes, local anesthesia was applied by the surgeon. Peribulbar block and periorbital infiltration application were performed by applying a mixture of lidocaine (Jetokain, Adeka, Turkey) and 1/200000 adrenaline. After the local anesthetic agent was applied by the surgeon, orbital compression was provided for 5 minutes with maximum pressure to block the eyelid movements. Cataract surgery procedures of all patients included in the study were performed by the same surgeon.
Trial: NCT01288079
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, oral, twice daily for 8 weeks
Trial: NCT05976100
Drug: NIOCH-14, 200 mg capsule: 1 capsule (200 mg) of NIOCH-14 once orally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volunteers take 1 capsule (200 mg) of NIOCH-14 as a single oral dose.
Trial: NCT05976100
Drug: NIOCH-14, 200 mg capsule: 3 capsules (200 mg each) of NIOCH-14 once orally. (Total 600 mg NIOCH-14 per day)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volunteers take 3 capsules (200 mg each) of NIOCH-14 as a single oral dose. (Total 600 mg NIOCH-14 per day)
Trial: NCT05976100
Drug: NIOCH-14, 200 mg capsule: 6 capsules (200 mg each) of NIOCH-14 per day orally. (Total 1200 mg NIOCH-14 per day)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 1200-mg oral dose. (1200-mg dose of the drug is administered by 600 mg twice a day at 8-00 and 20-00 in the hospital and presence of a clinical investigator or a nurse).
Trial: NCT05976100
Drug: NIOCH-14, 200 mg capsule: 1 capsule (200 mg) of NIOCH-14 a day orally for 6 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volunteers take 1 capsule (200 mg) of NIOCH-14 a day orally for 6 days.
Trial: NCT05976100
Drug: NIOCH-14, 200 mg capsule: 3 capsules (200 mg each) of NIOCH-14 a day orally for 6 days. (Total 600 mg NIOCH-14 per day for 6 days)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volunteers take 3 capsules (200 mg each) of NIOCH-14 a day orally for 6 days.
Trial: NCT05976100
Drug: NIOCH-14, 200 mg capsule: 3 capsules (200 mg each) of NIOCH-14 twice a day orally for 6 days. (Total 1200 mg NIOCH-14 per day for 6 days)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volunteers take 3 capsules (200 mg each) of NIOCH-14 twice a day orally for 6 days.
Trial: NCT01036854
Drug: EUR-1025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally, 24 mg, daily for 6 days
Trial: NCT01036854
Drug: EUR-1025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally, 8 mg, twice daily over 6 consecutive days
Trial: NCT01036854
Drug: EUR-1025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally, 8 mg, three times a day over 6 consecutive days
Trial: NCT01036854
Drug: EUR-1025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally, 8 mg, 16 mg, 24 mg, daily, for 6 days
Trial: NCT03170544
Drug: MK-1092, 8.0 nmol/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-1092, 8.0 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants
Trial: NCT03170544
Drug: MK-1092, 16 nmol/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-1092, 16 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants
Trial: NCT03170544
Drug: MK-1092, 32 nmol/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-1092, 32 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants
Trial: NCT03170544
Drug: MK-1092, 64 nmol/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-1092, 64 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants
Trial: NCT03170544
Drug: Glargine 3.0 nmol/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glargine 3.0 nmol/kg, SC, as a single dose
Trial: NCT03170544
Drug: Lispro 1.2 nmol/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lispro (Humalog®), 1.2 nmol/kg, IV infusion SC over 3 hours as a single dose starting \~12 hours after MK-1092 administration.
Trial: NCT03170544
Drug: Placebo to glargine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to glargine, SC, as a single dose
Trial: NCT03170544
Drug: Placebo to MK-1092
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to MK-1092, SC, as a single dose
Trial: NCT02445716
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: It consists of a 12-week treatment with 300mcg of transdermal testosterone phase involving three study visits. Participants will attend at the Federal University of Sao Paulo in Brazil for their study visits.~Participants will be submitted to a physical examination including vital signs and breast and pelvic examination. Women who met the eligibility criteria is invited to attend a baseline randomization visit. They will be randomly assigned in a 1:1 ratio to receive a transdermal testosterone nanoemulsion (0.8g per dose) delivering 300 mcg/day testosterone or an identical placebo provided by Evidence Pharmaceuticals LTDA, SP, BRAZIL.~Women are asked to return all unused pumps, and treatment compliance was checked by counting weighting returned packs at their final visit.
Trial: NCT02445716
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It consists of a 12-week treatment with placebo phase involving three study visits. Participants will attend at the Federal University of Sao Paulo in Brazil for their study visits.
Trial: NCT01622673
Drug: TUMS® Ultra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 tablets TUMS® Ultra Strength (US) 1000 mg~Throughout the study, participants will continue to take raltegravir every 12 hours along with their other HIV medications. There will be a minimum of 2 days washout between treatment periods. On the day of co-dosing and intensive PK sampling, raltegravir will be dosed in the morning in a fasted state in all periods.
Trial: NCT01622673
Drug: MINTOX® Maximum Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL MINTOX® Maximum Strength (MS)~Throughout the study, participants will continue to take raltegravir every 12 hours along with their other HIV medications. There will be a minimum of 2 days washout between treatment periods. On the day of co-dosing and intensive PK sampling, raltegravir will be dosed in the morning in a fasted state in all periods.
Trial: NCT00443729
Drug: Comparator: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lopinavir (+) ritonavir 400/100 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment
Trial: NCT00443729
Drug: Comparator: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: raltegravir 400 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment
Trial: NCT02126514
Drug: AZD3293
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 subjects will receive AZD3293
Trial: NCT00443690
Drug: Comparator: Placebo (unspecified)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rolofylline Pbo 30 mg IV QD; 3 days
Trial: NCT02508337
Drug: XG-102
RxNorm normalized name: Ninjacof XG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of XG-102 versus placebo for the treatment of ocular inflammation and pain associated with cataract surgery
Trial: NCT02508337
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of XG-102 versus placebo for the treatment of ocular inflammation and pain associated with cataract surgery
Trial: NCT01841684
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for anacetrapib orally, once daily for 12 weeks
Trial: NCT01576354
Drug: Prolonged-release Fampridine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg tablet twice a day (every 12 hours), orally
Trial: NCT01576354
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet twice a day (every 12 hours), orally (matched placebo is provided as oval-shaped, white to off-white, matrix tablets. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, hydroxypropyl methylcellulose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, and titanium dioxide)
Trial: NCT00659711
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: will be placed on a placebo for 12 weeks.
Trial: NCT02426502
Drug: Conversion to Advagraf
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prograf treated patients will convert to Advagraf using a 1: 1 conversion for a period of one week. The dose will then be titrated based on tacrolimus trough levels obtained 7 days after conversion. Cyclosporine (Neoral) treated patients will initiate Advagraf 0.075 mg/kg/day, 24 hours after their last cyclosporine dose. Participants will be provided with Advagraf and instructed how to start this new medication
Trial: NCT01809275
Drug: QBECO
RxNorm normalized name: Quinolinate Benzodiazepine Ester Compound
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01809275
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03177824
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2, consists of 30 patients receiving placebo Oral Tablet 3times daily , followed by repeating the Doppler US scan serially to detect changes in the measured indices and then assess the neonatal outcome after delivery as regard birth weight and APGAR score
Trial: NCT03405831
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, gelatine capsules to ensure blinding, 1 capsule twice daily, for a period of 12 weeks
Trial: NCT04464174
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine administered orally (1000 mg/m2) twice a day, from day 1 to day 14, and rest from day 15 to day 21 of every 21-day cycle
Trial: NCT04369391
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet
Trial: NCT01797874
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo arm
Trial: NCT04881474
Drug: Ibuprofen 800 mg
RxNorm normalized name: ibuprofen 800 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 30-minute lasting iv infusion of 800 mg ibuprofen diluted with 0,9% saline via intravenous route every 6 hours.
Trial: NCT02352701
Drug: Noltec tab. 10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ilaprazole 10mg BID dosage form : delayed release tablet
Trial: NCT02352701
Drug: Cravit Tab. 500mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500mg, BID dosage form : film coated tablet
Trial: NCT01900769
Drug: Blood Volume Dilution
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01695616
Drug: Active drug
RxNorm normalized name: Capillary active drug
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01037218
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets via oral administration before an attempt at sexual intercourse.
Trial: NCT00897715
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg of placebo administered subcutaneously once a week for 12 weeks
Trial: NCT03711097
Drug: Vanish XT Dental Varnish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varnish will be applied to the front surface of the intervention upper central and lateral incisors
Trial: NCT03630497
Drug: Comparison of BN201 treatment with Placebo
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Dose or Multiple Dose of BN201 IV administration
Trial: NCT02881853
Drug: XmAb7195
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02881853
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00513240
Drug: Erythropoetin
RxNorm normalized name: Erythropoetin zeta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoetin 500 units/kg IV x 3 : dose 1. 12-72 hours preoperatively, dose 2. Postoperative day #1, 48 hours after separating from cardiopulmonary bypass, and dose 3. postoperative day #3, 48 hours after dose #2
Trial: NCT00513240
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline placebo in 3 doses:dose 1. 12-72 hours preoperatively, dose 2. Postoperative day #1, 48 hours after separating from cardiopulmonary bypass, and dose 3. postoperative day #3, 48 hours after dose #2.~.
Trial: NCT02695446
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral extended release minocycline
Trial: NCT02386319
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gelatin capsules
Trial: NCT02386319
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules
Trial: NCT04324424
Drug: HMS5552
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of HMS5552 25mg
Trial: NCT02954484
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule containing lactose and MCC (no active ingredients).
Trial: NCT02954484
Drug: Etoricoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 120mg per oral once daily on postoperative days 1,2,3. 'Arcoxia' manufacture site: MSD International GMBH, Singapore
Trial: NCT04162743
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: take placebo oral tablet before polysomnography
Trial: NCT00455403
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine Placebo tablet daily for 12 months followed by 12 months off drug with 1 visit at month 24
Trial: NCT02391688
Drug: Caffeine, omeprazole, flurbiprofen, dextromethorphan, midazolam
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00218387
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo
Trial: NCT03525561
Drug: Placebo pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take placebo pill and then we will assess exercise performance during 30-hour exposure to 3,500 m simulated altitude.
Trial: NCT03830489
Drug: polyethylene glycol plus ascorbic acid
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control arm will take 2 L polyethylene glycol solution (PEG) plus ascorbic acid in split dose plus 1 day of fiber-free diet